TNDM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tandem Diabetes Care Inc (TNDM) presents a compelling buy opportunity for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The stock is currently trading pre-market at $20.085, which is below the majority of analysts' price targets, indicating potential upside. Positive catalysts such as hedge fund buying, strong analyst upgrades, and the company's transition to a pharmacy model support long-term growth. While recent financial performance shows a net income decline, the gross margin improvement and revenue growth signal operational progress. The SwingMax signal from 2026-04-08 further supports a buy decision.
The MACD is positively expanding, indicating bullish momentum. RSI is neutral at 48.2, showing no overbought or oversold conditions. The stock is trading near its pivot level of 19.888, with resistance at 21.37 and support at 18.406. Moving averages are converging, suggesting a potential breakout. Overall, the technical indicators lean slightly bullish.
Hedge funds have significantly increased their buying activity by 870.81% in the last quarter.
Multiple analyst upgrades with price targets ranging from $22 to $56, citing revenue growth, improved margins, and the pharmacy model transition.
SwingMax signal from 2026-04-08 indicates a buy-low opportunity.
Gross margin improvement to 57.67% YoY.
Net income dropped significantly by -178.01% YoY in Q4
EPS declined by -200.00% YoY, reflecting profitability challenges.
No recent news or congress trading data to provide additional sentiment support.
In Q4 2025, revenue increased by 2.74% YoY to $290.38M, indicating growth. However, net income dropped to -$589,000 (-178.01% YoY), and EPS fell to -0.01 (-200% YoY). Gross margin improved to 57.67%, up 3.52% YoY, signaling operational efficiency gains despite profitability challenges.
Analysts are broadly optimistic about TNDM. Recent upgrades include Truist (Buy, $35 target), Piper Sandler (Overweight, $33 target), and Lake Street (Buy, $50 target). Analysts cite accelerating revenue growth, improved margins, and the pharmacy model transition as key drivers. The consensus reflects strong long-term growth potential despite near-term uncertainties.
